Description of the medicine: Lanreotide (Lanreotide)
Synonym: Somatulin, Somatuline.
Synthetic heptapeptide, similar in structure and action to endogenous somatostatin.
Powder in the form of lyophilized microspheres, characterized by phases of fast (from the surface) and slow release.
With max in the phases of fast and slow release, it is 0.6-2.2 hours and 0.1 and 3.7 days, respectively, bioavailability is about 30-60%, T Ѕ 2.7-7.7 days.
Indications, possible side effects and contraindications are the same as for octreotide.
With acromegaly and endocrine tumors of the gastro-entero-pancreatic system, 0.03 g (30 mg) is prescribed intramuscularly once every 10-14 days.
Release form: lyophilized powder for injection in vials of 0.03 g (30 mg) complete with a solvent.